Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Melatonin (meta)
Aspirin (meta) Metformin (meta)
Bamlaniv../e.. (meta) Molnupiravir (meta)
Bebtelovimab (meta) N-acetylcys.. (meta)
Bromhexine (meta) Nigella Sativa (meta)
Budesonide (meta) Nitazoxanide (meta)
Cannabidiol (meta) Nitric Oxide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)
Lactoferrin (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 14% Improvement Relative Risk ICU admission 28% ARDS 25% Hospitalization 2% c19aspirin.com Malik et al. Aspirin for COVID-19 Prophylaxis Favors aspirin Favors control
Malik, 310 patient aspirin prophylaxis study: 14% lower mortality [p=0.72], 28% lower ICU admission [p=0.17], 25% lower ARDS [p=0.39], and 2% lower hospitalization [p=0.94] https://c19p.org/malik
copied to clipboard
Effect of low dose acetylsalicylic acid and anticoagulant on clinical outcomes in COVID‐19, analytical cross‐sectional study
Malik et al., Health Science Reports, doi:10.1002/hsr2.699
11 Jul 2022    Source   PDF   Share   Tweet
Retrospective 539 patients in the USA, showing lower mortality, ICU admission, and ARDS with aspirin treatment, without statistical significance.
risk of death, 13.6% lower, RR 0.86, p = 0.72, treatment 15 of 87 (17.2%), control 24 of 223 (10.8%), adjusted per study, odds ratio converted to relative risk, multivariable.
risk of ICU admission, 27.8% lower, RR 0.72, p = 0.17, treatment 28 of 87 (32.2%), control 77 of 223 (34.5%), adjusted per study, odds ratio converted to relative risk, multivariable.
risk of ARDS, 25.1% lower, RR 0.75, p = 0.39, treatment 13 of 87 (14.9%), control 40 of 223 (17.9%), NNT 33, adjusted per study, odds ratio converted to relative risk, multivariable.
risk of hospitalization, 2.4% lower, OR 0.98, p = 0.94, treatment 25, control 176, adjusted per study, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Malik et al., 7/11/2022, retrospective, USA, peer-reviewed, 16 authors, study period 1 March, 2020 - 1 December, 2020.
Contact: muhammadbmalik@gmail.com, dr_samar11@yahoo.com.
All Studies   Meta Analysis
This PaperAspirinAll
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit